KNSA

Kiniksa Pharmaceuticals International, plc

KNSA · CIK 1730430 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$678M
20182025
Net Income$59M
20182025
Operating CF$138M
20182025
Free Cash Flow$136M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.7B$0.4B$0.3B$0.2B$0.0B———
Cost of Revenue$0.1B$0.1B——$0.0B———
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense$0.2B$0.2B$0.1B$0.1B$0.1B———
Operating Income$0.1B$-0.0B$-0.0B$0.0B$-0.2B$-0.2B$-0.2B$-0.1B
Net Income$0.1B$-0.0B$0.0B$0.2B$-0.2B$-0.2B$-0.2B$-0.1B
EPS (Basic)$0.80$-0.60$0.20$2.64$-2.30———
EPS (Diluted)$0.75$-0.60$0.20$2.60$-2.30———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.8B$0.6B$0.5B$0.5B$0.2B$0.3B$0.3B$0.3B
Current Assets$0.5B$0.3B$0.3B$0.2B$0.2B$0.3B$0.2B$0.3B
Cash & Equivalents$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B$0.0B$0.1B
Total Liabilities$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.6B$0.4B$0.4B$0.4B$0.2B$0.3B$0.2B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.1B$0.0B$0.0B$0.0B$-0.1B$-0.1B$-0.2B$-0.1B
Investing Cash Flow$-0.2B$0.0B$-0.0B$-0.0B$0.1B$-0.0B$0.0B$-0.2B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.2B$0.1B$0.3B
← Companies